Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial).

MLA

Shimizu, Hisanori, et al. “Economic Analysis of Palonosetron versus Granisetron in the Standard Triplet Regimen for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan (TRIPLE Phase III Trial).” Journal of Pharmaceutical Health Care and Sciences, vol. 4, Dec. 2018, p. 31. EBSCOhost, https://doi.org/10.1186/s40780-018-0128-9.

APA

Shimizu, H., Suzuki, K., Uchikura, T., Tsuji, D., Yamanaka, T., Hashimoto, H., Goto, K., Matsui, R., Seki, N., Shimada, T., Ikeda, S., Ikegami, N., Hama, T., Yamamoto, N., & Sasaki, T. (2018). Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). Journal of Pharmaceutical Health Care and Sciences, 4, 31. https://doi.org/10.1186/s40780-018-0128-9

Chicago

Shimizu, Hisanori, Kenichi Suzuki, Takeshi Uchikura, Daiki Tsuji, Takeharu Yamanaka, Hironobu Hashimoto, Koichi Goto, et al. 2018. “Economic Analysis of Palonosetron versus Granisetron in the Standard Triplet Regimen for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan (TRIPLE Phase III Trial).” Journal of Pharmaceutical Health Care and Sciences 4 (December): 31. doi:10.1186/s40780-018-0128-9.